Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 255

1.
2.

Efficacy of selected treatments of HIV wasting: a systematic review and meta-analysis.

Moyle GJ, Schoelles K, Fahrbach K, Frame D, James K, Scheye R, Cure-Bolt N.

J Acquir Immune Defic Syndr. 2004 Dec 1;37 Suppl 5:S262-76. Review.

PMID:
15722869
4.

[The use of growth hormone to treat endocrine-metabolic disturbances in acquired immunodeficiency syndrome (AIDS) patients].

Spinola-Castro AM, Siviero-Miachon AA, da Silva MT, Guerra-Junior G.

Arq Bras Endocrinol Metabol. 2008 Jul;52(5):818-32. Review. Portuguese.

5.

Spotlight on mammalian cell-derived somatropin in HIV-associated wasting.

Goldsmith DR, Wagstaff AJ.

BioDrugs. 2006;20(3):191-2. Review.

PMID:
16724867
6.

Counteracting muscle wasting in HIV-infected individuals.

Dudgeon WD, Phillips KD, Carson JA, Brewer RB, Durstine JL, Hand GA.

HIV Med. 2006 Jul;7(5):299-310. Review.

7.
8.

HIV-associated wasting in the era of HAART: a practice-based approach to diagnosis and treatment.

Steinhart CR.

AIDS Read. 2001 Nov;11(11):557-60, 566-9. Review.

PMID:
11789018
9.

Cachexia: pathophysiology and clinical relevance.

Morley JE, Thomas DR, Wilson MM.

Am J Clin Nutr. 2006 Apr;83(4):735-43. Review.

10.

Growth hormone in HIV/AIDS: current uses and future prospects.

Laurence J.

Pediatr AIDS HIV Infect. 1995 Oct;6(5):281-91. Review.

PMID:
11361393
11.

Anabolic treatment with GH, IGF-I, or anabolic steroids in patients with HIV-associated wasting.

Mulligan K, Schambelan M.

Int J Cardiol. 2002 Sep;85(1):151-9. Review.

PMID:
12163220
12.

Growth hormone therapy for protein catabolism.

Jenkins RC, Ross RJ.

QJM. 1996 Nov;89(11):813-9. Review.

PMID:
8977960
13.

Human immunodeficiency virus-associated wasting and mechanisms of cachexia associated with inflammation.

Moldawer LL, Sattler FR.

Semin Oncol. 1998 Feb;25(1 Suppl 1):73-81. Review.

PMID:
9482543
14.

Pathophysiology of body composition and metabolic abnormalities in HIV-infection: therapeutic implications.

Hellerstein MK.

Int J Sport Nutr Exerc Metab. 2001 Dec;11 Suppl:S105-10. Review.

PMID:
11915908
15.
16.

Recombinant human growth hormone: rationale for use in the treatment of HIV-associated lipodystrophy.

Benedini S, Terruzzi I, Lazzarin A, Luzi L.

BioDrugs. 2008;22(2):101-12. Review.

PMID:
18345707
17.

Growth hormone and HIV infection: contribution to disease manifestations and clinical implications.

Falutz J.

Best Pract Res Clin Endocrinol Metab. 2011 Jun;25(3):517-29. doi: 10.1016/j.beem.2010.11.001. Review.

PMID:
21663844
18.

Single-agent/combination therapy of human immunodeficiency virus-related wasting.

Wanke C.

Semin Oncol. 1998 Apr;25(2 Suppl 6):98-103. Review.

PMID:
9625391
19.

Body composition studies in HIV-infected individuals.

Kotler DP.

Ann N Y Acad Sci. 2000 May;904:546-52. Review.

PMID:
10865803
20.

Systematic review: the safety and efficacy of growth hormone in the healthy elderly.

Liu H, Bravata DM, Olkin I, Nayak S, Roberts B, Garber AM, Hoffman AR.

Ann Intern Med. 2007 Jan 16;146(2):104-15. Review.

PMID:
17227934

Supplemental Content

Support Center